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AbsTrACT
Global Health has not featured as prominently in the 
European Union (EU) research agenda in recent years 
as it did in the first decade of the new millennium, and 
participation of low-income and middle-income countries 
(LMICs) in EU health research has declined substantially. 
The Horizon Europe Research and Innovation Framework 
adopted by the European Parliament in April 2019 for the 
period 2021–2027 will serve as an important funding 
instrument for health research, yet the proposed health 
research budget to be finalised towards the end of 2019 
was reduced from 10% in the current framework, Horizon 
2020, to 8% in Horizon Europe. Our analysis takes the 
evolvement of Horizon Europe from the initial framework 
of June 2018 to the framework agreed on in April 2019 
into account. It shows that despite some improvements in 
terms of Global Health and reference to the Sustainable 
Development Goals, European industrial competitiveness 
continues to play a paramount role, with Global Health 
research needs and relevant health research for LMICs 
being only partially addressed. We argue that the globally 
interconnected nature of health and the transdisciplinary 
nature of health research need to be fully taken into 
account and acted on in the new European Research 
and Innovation Framework. A facilitated global research 
collaboration through Horizon Europe could ensure that 
Global Health innovations and solutions benefit all parts of 
the world including EU countries.
InTroduCTIon
Global Health evolved from the concepts of 
public1 and international health2 3 to form 
a ‘system-based, ecological and transdisci-
plinary approach to research, education, 
and practice which seeks to provide innova-
tive, integrated, and sustainable solutions 
to address complex health problems across 
national boundaries and improve health for 
all’ (p 155).4 Important components of Global 
Health include health equity, a focus on 
health issues transcending national borders, 
determinants of health, interdisciplinary and 
international collaboration and a ‘health for 
all’ approach.2–9
Global Health aims to overcome the 
national–international divide9 and that 
between high-income countries (HICs) and 
low-income and middle-income countries 
(LMICs) through mutual exchange and part-
nership, including joint funding, agenda 
setting, planning and implementation.2 3 10 
In doing so, Global Health aims to address 
the 10/90 gap,11 the disparity between global 
health research spending and disease burden 
in LMICs. However, the formation of genuine 
summary box
 ► Horizon Europe, the new European Union Research 
and Innovation Framework for the period 2021–
2027, will play an important role for health research 
globally.
 ► The overall visibility of Global Health and the partic-
ipation of low-income and middle-income countries 
(LMICs) have declined at EU level in recent years, 
and Horizon Europe barely mentions Global Health 
and LMICs.
 ► Innovation is equated with industrial competitive-
ness of European companies rather than effective 
and cost-saving innovations that could benefit EU 
countries and LMICs alike.
 ► The relative budget allocated to health shows a de-
cline from 10% in the current framework, Horizon 
2020, to 8% in Horizon Europe.
 ► More international, transdisciplinary and equitable 
research collaboration and broader access to Global 
Health research funding is needed, especially for 
LMICs, to ensure that future health research is based 
on the Sustainable Development Goals and address-
es the major health challenges the world is facing.  on
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research partnerships remains a challenge,3 10 12 as does 
the prioritisation of research targeted at high disease 
burden populations.2 These challenges are highlighted 
by the increasing mobility of the global population13 14 
and the rapid rise of non-communicable diseases with 
complex social determinants that require transdisci-
plinary scientific approaches4 15 and innovative solu-
tions.16 17
This paper emanated from a transdisciplinary meeting 
of European Global Health research institutes with a 
non-governmental global development organisation in 
Brussels in July 2018. The 22 participants in this two-day 
meeting represented European Global Health researchers 
from Belgium (University of Antwerp), Germany 
(Ruprecht-Karls-University, Heidelberg, Ludwig-Maxi-
milians-University, Munich), Italy (University of Milan), 
Spain (University of Barcelona), Sweden (Lund Univer-
sity), Switzerland (University of Geneva), the Nether-
lands (University of Amsterdam, University of Leiden, 
Utrecht University), the UK (Imperial College London, 
University College London, University of Oxford) and a 
non-governmental organisation (NGO) for global devel-
opment, Deutsche Stiftung Weltbevölkerung (DSW). A 
Future Search Conference methodology18–20 was used to 
assess developments in Global Health at individual insti-
tutions, across Europe and globally. With the European 
Commission publishing a new European Research and 
Innovation (R&I) Framework, Horizon Europe, partici-
pants analysed European health R&I priorities based on 
Global Health challenges and with the aim to strengthen 
Global Health considerations in this framework. Negotia-
tions between the Council of the European Union (EU) 
and the European Parliament led to modifications in the 
Horizon Europe Framework. The negotiating process 
was informed by the positions of various actors—private 
sector, NGOs and academic institutions—including 
that of the European Global Health Research Institutes 
Network (EGHRIN), a network formed at the Brussels 
meeting in July 2018, see https//eghrin-eu. To illus-
trate important text and structural changes in Horizon 
Europe with regard to Global Health, this paper refers 
to the initially proposed framework and regulation docu-
ments by the European Commission of June 201821–24 as 
well as subsequent versions in late 201825 26 leading to the 
documents agreed on by EU institutions and approved 
by the European Parliament in April 2019.27 28 The EU 
R&I Framework is analysed and appraised from a Global 
Health perspective and with reference to the Sustainable 
Development Goal (SDG) framework.29
Eu EfforTs on GlobAl HEAlTH In THE lAsT dECAdE
Global Health came to prominence on the European 
agenda with the EU‘s first health strategy and policy 
framework in 2007 and Council Conclusions on Global 
Health in 2010.30 The 2010 Council Conclusions set out 
to advance a visionary Global Health agenda focused on 
strengthening collaborative research capacity; developing 
affordable medical products; dissociating Research & 
Development (R&D) costs from intellectual property 
considerations; ensuring that access to knowledge and 
tools form part of the R&D agenda; and strengthening 
health systems to measure progress on the social deter-
minants of health.31 Yet, instead of being the starting 
point for greater Global Health research engagement, 
the EU Communication and Council Conclusions largely 
remained a statement rather than a plan for action30 and 
few member states developed their own Global Health 
policies.32
The EU Communication on its role in Global Health33 
emphasised the aspect of ‘protection against Global 
Health threats’ (p 2). Protection was, however, mainly 
defined in terms of strengthening ‘global and third coun-
tries’ national capacities of early prediction, detection 
and response to Global Health threats’ (p 8) rather than 
focusing on cross-border health threats, which became 
more prominent in recent publications of the EU.27 34 
This led to the question of whom health security is for35 36 
or even what it should entail37 or how ‘security’ should 
be defined and specified.38 Global Health strategies with 
a self-interested security concern can also be perceived in 
the policies of member states such as the UK, Germany 
and France.32 Security concerns relate to a regionalisa-
tion of local epidemic outbreaks, the threat of terrorism 
from impoverished regions, and conflict over resources 
due to climate change, to name a few.39 The heightened 
concern for security and the persistent after-effects of 
the 2008 financial crisis led to Europe’s 2020 strategy, 
which focused primarily on job creation and economic 
growth.40
Germany used its presidencies of the G7 and G20 
summits in 2015 and 2017 to give more prominence to 
Global Health.41 42 Yet, Global Health has largely fallen 
off the EU research agenda.22 27 28
nEw EuropEAn r&I frAmEwork—HorIzon EuropE
Horizon Europe lists health as one of six clusters in ‘Global 
Challenges and European Industrial Competitiveness’,27 
the second pillar of the programme. The other two 
pillars are ‘Excellent Science’ and ‘Innovative Europe’,27 
see figure 1. The health cluster is divided into six priority 
areas: health throughout the life course; environmental 
and social health determinants; non-communicable and 
rare diseases; infectious diseases, including poverty-re-
lated and neglected diseases (PRND); tools, technolo-
gies and digital solutions for health and care, including 
personalised medicine, and healthcare systems.28
Horizon 2020 is the EU’s current R&I Framework 
Programme (2014–2020) with a budget of €80 billion34 43 
with 10% earmarked for health.34 The European Commis-
sion proposed the successor programme Horizon Europe 
in 2018, with a budget of €94.1 billion for 2021–2027 
including €7.7 billion, or 8%, earmarked for health.23 
The draft documents were discussed by the Council of 
the EU and the European Parliament and altered with 
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Figure 1 Horizon Europe R&I Framework based on the Common Understanding reached between Council and European 
Parliament on 27 March 2019 and the Partial General Agreement of 15 April 2019. Italicized text indicates changes in the 
Framework agreed upon by EU institutions in 2019.
some improvements on Global Health language and 
concepts27 28 while at the same time emphasising Euro-
pean innovations, see figure 1. The Council upheld multi-
dimensionality in addressing global challenges, among 
others through R&I missions,25 28 yet did not increase the 
budget proposal of the European Commission of €94 
billion. Contrary to the Council, the European Parliament 
proposed an overall research budget for Horizon Europe 
of €120 billion,26 with the health cluster receiving 8.16% 
or €9.79 billion of the overall budget.44 The budget was 
not part of the final Horizon Europe Framework of April 
2019 and will be negotiated as part of the multiannual 
financial framework in 2019.45
AnAlysIs of Eu r&I frAmEwork
What follows is a European Global Health institutes’ anal-
ysis of Global Health issues in the current and previous 
Horizon Europe frameworks.21–24 27 28 46 47 SDGs and 
industrial competitiveness and innovation, which are 
central themes in the Horizon Europe Framework, are 
also considered in this analysis. Further themes such as 
funding, health systems, environmental and social health 
determinants and more detailed information on Global 
Health, PRND, LMICs, networking and participation are 
listed in the online supplementary table 1.
sdGs, Global Health, one Health and Horizon Europe
The move from the Millennium Development Goals to 
the SDGs calls for interdisciplinary and transdisciplinary 
approaches29 48 and thus can be seen as strengthening 
Global Health endeavours. Infectious and non-communi-
cable diseases and environmental health risks are a world-
wide concern and not limited to individual countries or 
regions;49 an adequate response therefore needs to be 
global and interconnected. The Horizon Europe Frame-
work links the health cluster only to SDGs 3 (good health 
and well-being)27 and 13 (climate action);27 its intercon-
nectedness with other SDGs is not specifically mentioned 
despite the EU’s ‘health in all policies’ approach of 2006 
which is lagging behind in implementation.50 In the 
course of the negotiations of the Horizon Europe Frame-
work, SDG references increased from 4522–24 to 57,27 28 yet 
the health cluster continues to be linked only to ‘health’ 
and ‘climate action’.27 Locating health at the centre of all 
other SDGs and linking health aspects with all other clus-
ters in the Horizon Europe Framework would underscore 
the importance of Global Health in working towards the 
achievement of the SDGs and the contribution of the 
SDGs to Global Health51 with a view to achieving planetary 
health.6 This would incorporate a One Health approach, 
which is mentioned several times in the Horizon Europe 
Framework27 in connection with antimicrobial resistance 
(AMR), an area for which the EU is an important global 
actor.52 While Horizon Europe acknowledges that ‘health 
challenges are complex, interlinked and global’ (p 19),22 
the final framework has placed the term ‘Global Health’ 
in the context of infectious diseases.27 Notwithstanding 
the importance of infectious diseases and the crucial 
addition of PRND in the final framework,27 Global Heath 
has to be understood as a broader concept in terms of 
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content and geographic scope.2 4 Even in the final frame-
work, LMICs only merit one reference,27 and their partic-
ipation in R&I has decreased substantially in the current 
Horizon 2020 programme compared with the EU Frame-
work Programme 7.46 This is also reflected in access to 
EU funding (https:// webgate. ec. europa. eu/ dashboard/ 
sense/ app/ 93297a69- 09fd- 4ef5- 889f- b83c4e21d33e/ 
sheet/ PbZJnb/ state/ analysis) and in contrast to the 
EU’s R&I ‘open to the world policy’.53 Equitable research 
participation is thus still a vision rather than reality.
European industrial competitiveness, innovation and Global 
Health
‘Industrial competitiveness’ is mentioned 14 times and 
‘industry’ 67 times in the Horizon Europe Decision27 as 
well as 13 times in the Regulation28 clearly showing that 
the EU’s paramount concern for R&I is economic. The 
term ‘Global Health’, by contrast, is only mentioned 
three times.27 28 The linking of innovation to industrial 
competitiveness and economic growth27 is problematic, 
as Walsh and colleagues43 pointed out with regard to 
the current R&I programme, Horizon 2020, criticising 
the 'particularly narrow interpretation of the health 
and wealth agenda, regarding health research as a lever 
for economic growth through patentable technological 
advances, exploitable intellectual property and the indus-
trialisation of invention and innovation' (p 669).
Labonté and Gagnon39 point out the danger of health 
inequity through trade and intellectual property rights 
especially for poorer countries. The interests of industry 
and the needs of patients for ‘affordable, cost-effec-
tive, clinically relevant, user responsive innovations’ (p 
1403)54 differ, and many countries are not in a position 
to afford the latest health technology or innovation.43 54
The pharmaceutical industry has shown little interest 
in developing products regarded as non-profitable, such 
as an investment in new antibiotics (see EU Action Plan 
against AMR 2011, https:// ec. europa. eu/ health/ amr/ 
sites/ amr/ files/ communication_ amr_ 2011_ 748_ en. pdf, 
p 8). This has aggravated the Global Health burden in 
terms of AMR.55 56 The same holds true for PRND.57 58 
Since 2016, more engagement by pharmaceutical and 
diagnostic companies on AMR research has been notice-
able following an industry declaration (https://www. 
ifpma. org/ resource- centre/ declaration- by- the- pharma-
ceutical- biotechnology- and- diagnostics- industries- on- 
combating- antimicrobial- resistance/) and the emergence 
of more public–private partnerships (https:// acce ssto 
medi cine foun dation. org/ amr- benchmark/ about- the- 
benchmark/ the- context), many of them initiated by the 
EU59 which has been a major funder for PRND.60 The EU 
has addressed AMR in strategies and action plans since 
2001 (https://www. eca. europa. eu/ lists/ ecadocuments/ 
ap19_ 03/ ap_ amr_ en. pdf) and supported joint African 
and European research for AMR and PRND through 
the European and Developing Countries Clinical Trials 
Partnership (EDCTP) for research and product develop-
ment.61–66 In the 2011 EU action plan on AMR, the lack 
of new antimicrobial agents was addressed by launching 
new programmes under the Innovation Medicines Initia-
tive (https:// ec. europa. eu/ health/ amr/ sites/ amr/ 
files/ communication_ amr_ 2011_ 748_ en. pdf page 9; 
https://www. imi. europa. eu/), the EU’s largest public–
private partnership. This initiative has been criticised for 
its industry-driven research agenda and non-transparent 
decision-making67 68 as well as its lack of support to small-
sized and medium-sized enterprises67 and for the health 
needs and participation of LMICs (https:// eghrin. eu/).
The ‘innovation principle’ of the EU27 is a case in point 
for the dominance of industrial concerns. This ‘principle’ 
has been lobbied for by European companies since 2013 
(https:// corporateeurope. org/ sites/ default/ files/ corpo-
ration_ letter_ on_ innovation_ principle. pdf) and can be 
seen as an attempt by European industries to weaken the 
‘precautionary principle’ (for a definition, see https:// eur- 
lex. europa. eu/ summary/ glossary/ precautionary_ prin-
ciple. html),69 which is mentioned as a guiding principle in 
Horizon Europe.27 Despite the vagueness and ambiguity of 
this term,70 the precautionary principle has safeguarded 
the health of European citizens through, for example, a 
ban on the export of bovine animals from the UK at the 
time of the BSE scandal in the late 1990s (http:// curia. 
europa. eu/ juris/ showPdf. jsf; jsessionid= 9ea7 d0f1 30d6 
a4ba 8562 0a86 4bb1 accc de4f ffad75ac. e34K axiL c3eQ c40L 
axqM bN4P ahaOe0? text=& docid= 101067& pageIndex= 
0& doclang= EN& mode= lst& dir=& occ= first& part= 1& cid= 
303969). For the first time, the industry-backed ‘innovation 
principle’ (defined as ‘whenever precautionary legislation 
is under consideration, the impact on innovation should 
also be taken into full account in the policy and legislative 
process’, see https:// corporateeurope. org/ sites/ default/ 
files/ corporation_ letter_ on_ innovation_ principle. pdf) 
has been incorporated into an EU R&I Framework, 
Horizon Europe, despite civil society and political parties 
alerting to the possibility of increased risks to human 
health and ‘thwarting long-established and settled EU 
environmental principles’ (p 12)69 (https:// corporateeu-
rope. org/ en/ environment/ 2018/ 12/ innovation- prin-
ciple- trap; https://www. greens- efa. eu/ en/ article/ news/ 
the- innovation- principle- is- a- regulatory- trojan- horse- from- 
the- industry/; https:// epha. org/ removing- innovation- 
principle- from- horizon- europe/). The decision to include 
the ‘innovation principle’ therefore raises questions about 
the influence of industry at EU level and whom the EU sees 
as beneficiaries of ‘innovations’. EU initiatives to advance 
needed innovations should operate under the precau-
tionary principle and fulfil responsible R&I requirements 
(https:// ec. europa. eu/ programmes/ horizon2020/ en/ 
h2020- section/ responsible- research- innovation),69 71 both 
of which are mentioned in Horizon Europe.27
Rather than equating the ‘precautionary principle’ with 
thwarting progress and innovation, constraints can stim-
ulate creative solutions as has been shown in LMICs with 
many advancements in health.72 73 EU member states could 
benefit from these innovations with regard to effective 
and cost-efficient health products, strengthened health 
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systems and health information as well as better service 
delivery.72–79 Cost-effectiveness is mentioned in terms of 
tools27 and health systems27 28 in Horizon Europe, and one 
way to advance cost-effective innovations would be for the 
EU to strengthen partnerships between LMICs and HICs 
such as the EDCTP. This programme is an effective part-
nership between African and European health institutes 
in terms of planning and conducting innovative health 
research for PRND and in terms of collaboration and 
joint oversight.64–66 EDCTP has shown success in devel-
oping medicines, vaccines and diagnostics (http://www. 
edctp. org/ web/ app/ uploads/ 2018/ 09/ Tackling- infec-
tious- disease- in- sub- Saharan- Africa_ EDCTP- funded- clin-
ical- studies- for- medical- interventions- 2003- 2018- 4. pdf) 
and could benefit from a higher budget and geographic 
expansion. With a successor programme to the current 
partnership programme being negotiated, the mention of 
Global Health as a possible area for partnership is helpful;28 
however, negotiations for an EU-Africa Global Health Part-
nership increasingly focus on health security, which may 
indicate a shift in the priorities of the EDCTP successor 
programme (Science Business, 20 May 2019; https:// 
sciencebusiness. net/ framework- programmes/ news/ more- 
details- emerge- 44- possible- horizon- europe- partnerships. 
List of candidates for European partnerships available at 
https:// sciencebusiness. net/ sites/ default/ files/ inline- 
files/ HE- partnerships. pdf).
A vIsIon for GlobAl HEAlTH rEsEArCH
In a global and interlinked world, there is a need for equi-
table,10 well-funded innovative health research between 
LMICs and HICs79 that addresses interconnected health 
issues: climate change; migration; access to food and 
water; the spread of diseases and epidemics; the devel-
opment of new, needed and affordable diagnostics and 
medicines; and the strengthening of health systems to 
significantly decrease the global disease burden49 and 
to improve health equity while ensuring consistency 
between (European) health and trade policies.7 39 80 Such 
R&I could be a catalyst for the implementation of the 
SDGs and a move towards a One Health and eventually a 
Planetary Health approach.6 Global Health research and 
cost-effective solutions would also benefit HICs, such as 
European member states, that increasingly struggle with 
high medicine prices and an overstretched work force, a 
problem well-known to LMICs.73 74 79 In order to devise 
global solutions to global problems, cooperation not only 
needs to involve LMICs but also extend beyond research 
institutions to civil society (eg, NGOs) and governments.4 
This would ensure that key stakeholders have a voice in the 
R&I agenda and facilitate implementation at the national 
level while strengthening a transdisciplinary research 
approach. The equitable cooperation of research insti-
tutes globally is also a crucial element for advancing 
Global Health research, yet should take the key element 
of governance into account.81 This vision of equitable 
research in Global Health supported by the EU is based 
on the Decision document, which foresees improved 
pan-European and regional collaboration.27 Yet, further 
globalisation of this vision is needed to enable institutions 
in LMICs to better access direct funding for health R&I 
and to lead on much needed research in Global Health. 
This could also be achieved through a strengthening and 
widening of the EU partnership programme EDCTP as 
well as Global Health research networks.
ConClusIon
The discussion and analysis of the proposed Horizon 
Europe R&I Framework by European researchers 
engaged in Global Health confirmed the importance of 
the EU and this framework for health R&I, yet found it 
wanting in terms of a genuine Global Health approach 
despite some improvements to the framework during 
the negotiating process. European industrial interests 
were found to dominate with regard to Global Health 
innovations; LMIC participation, by contrast, is hardly 
mentioned in the framework.
Aluttis and colleagues30 in analysing Global Health 
in relation to the EU remark that ‘the EU remains 
a forceful actor in the world which can speak with a 
strong voice on health matters of global concern’ (p 
6). In order to maintain this role, the EU will need 
to fully embrace the concept of Global Health in the 
implementation of its R&I agenda and facilitate and 
adequately fund joint Global Health research to ensure 
that health innovations benefit all parts of the world. 
Special Horizon Europe funding calls with an intent 
to increase participation of LMIC research institutes 
could directly benefit the EU through effective and 
cost-saving innovations in and from LMICs and their 
transfer to Europe. The EU would therefore benefit 
from strengthening partnership programmes such as 
EDCTP or by facilitating funding for global research 
networks that include research institutions based in 
LMICs and work in a transdisciplinary way with equi-
table governance structures.
Applying a Global Health concept and strategy to 
the framework would show effects beyond health, as 
Speakman and colleagues82 comment: ‘A prominent 
EU Global Health strategy would not only benefit 
Global Health. It would also show leadership from 
Europe, promoting the values of which the EU is justi-
fiably proud: respect for human dignity and human 
rights, freedom, democracy, equality…’ (p e393). An 
enhanced EU strategy on Global Health could help 
invigorate world class health research with tangible 
Global Health outcomes and sustainable Global Health 
innovations for coming generations.
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